V
Ventyx Biosciences
A biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets
About Ventyx Biosciences
Ventyx Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm, directing its efforts toward the development of selective, small molecule oral therapies for a range of autoimmune diseases. The company, which was founded in 2018, is headquartered in San Diego, California. Its establishment was the result of the merger of three companies: Oppilan Pharma, Zomagen Biosciences, and Ventyx, all of which were portfolio companies of New Science Ventures. This strategic consolidation brought together a diversified pipeline of clinical and preclinical assets aimed at immunology.
Read full description
The company's business model is centered on identifying and advancing promising drug candidates through the various stages of clinical development. Ventyx targets the immunology and inflammation markets, developing treatments for conditions such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Its revenue generation is prospective, contingent upon the successful commercialization of its product candidates or through strategic partnerships and licensing agreements with other pharmaceutical companies.
Ventyx's drug pipeline features several candidates. VTX958 is a tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of psoriasis, psoriatic arthritis, and Crohn's disease. Another key asset is VTX002, a sphingosine 1 phosphate receptor (S1P1R) modulator developed for patients with moderate-to-severe ulcerative colitis. The portfolio also includes VTX2735, a peripherally restricted NLRP3 inhibitor, and VTX3232, a CNS-penetrant NLRP3 inhibitor, targeting systemic and neuroinflammatory diseases. These molecules are designed to be taken orally, offering a potential convenience advantage over injectable biologics that currently dominate the market for many autoimmune disorders. In October 2021, Ventyx Biosciences successfully launched its initial public offering (IPO), raising approximately $174.3 million in gross proceeds to fund its research and development activities.
At a glance
- Founded
- 2018
- Headquarters
- Encinitas, United States
- Listing
- IPO 2021
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Latest news
Press, funding announcements and product moves mentioning Ventyx Biosciences.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A14 investors entered at this stage
Farallon Capital Management
Wellington Management
Qiming Venture Partners USA
Citadel
OrbiMed
Cormorant Asset Management
venBio Partners
RTW Investments
Logos Capital
New Science Ventures
Vivo Capital
Janus Henderson Investors
Third Point
Surveyor Capital
Series B and later8 investors entered at this stage
Redmile Group
EcoR1 Capital
CaaS Capital Management
Great Point Partners
Driehaus Capital Management
Walleye Capital
Woodline Partners
Sanofi
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
16 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ventyx Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ventyx Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.